

Preview of Abstract #17066

[Dashboard](#)[Abstract Submissions](#)[Preview of Abstract #17066](#)[Back](#)

MAIN INFORMATION

Abstract submitted

Title

Developing a novel computer-aided diagnostic technique based on deep learning and CT images for early HCC diagnosis

Preferred Presentation Format

Oral Presentation

Poster Presentation Format

-

Student Presentation Format

-

Topic

Artificial Intelligence & Machine Learning

Support programme applications

none

Authors

O. Lucidarme¹, V. Paradis², C. Guettier³, I. Brocheriou¹, J. Shen⁴, S. Poullot⁴, V. K. LE⁴, V. Vilgrain², M. Lewin-Zeitoun³; ¹Paris/FR, ²Clichy/FR, ³Villejuif Cedex/FR, ⁴Valbonne/FR

BODY

studied a novel computer-aided diagnostic technique, based on deep learning (DL) to assist radiologists in improving the diagnosis accuracy on CT scans.

Methods or Background

The proposed DL model is a combination of a specifically designed convolutional 3D classifier and a state-of-the-art 3D detector (3D-RetinaUnet). It leverages the arterial and portal venous phases of CT scans as input and provides the locations of HCCs as output. The dataset is part of the Phenotyping Liver Cancer Registry (NCT04681274), which collects multiphase CT, and clinical data of liver cancer patients from multiple French sites (La Pitié-Salpêtrière, Beaujon and Paul Brousse).

Results or Findings

The training dataset is comprised of 705 CT scans with 1159 HCCs annotated by 3 expert radiologists. The test dataset consisted of 179 CT scans in which 181 HCCs were histopathologically confirmed, including 12 HCCs of small size (20 mm or less) and 42 of size between 20 and 30 mm. Our DL model reached a sensitivity of 75% for diagnosing HCCs between 10 and 20 mm, 88% for HCCs between 20 and 30 mm, and 98% for HCCs exceeding 30 mm in size with an average of 3 false positives per scan.

Conclusion

Our DL model could increase HCC diagnosis accuracy compared to state of the art (Sensitivity of 64% for diagnosing small HCCs). The next step is to refine our DL model further and augment the training dataset with more at-risk patients with small lesions.

Limitations

Lack of at-risk patients (benign patients) data and limited number of patients with early stage HCC for training and testing the algorithm.

Funding for this study

APHP and Median entered into a research collaboration agreement according to which Median technologies provides funding to APHP institution for this research project, gathered the CT scans and made the AI analysis

Has your study been approved by an ethics committee?

Yes

Ethics committee - additional information

IRB Number : CRM-1911-042-C

MULTICATEGORIES

Imaging Technique

CT

Procedure

CAD, Computer Applications-Detection, diagnosis

Special Focus

Cancer, Cirrhosis

AFFIRMATIONS

Material used (mandatory)

X I affirm to the ESR that my abstract does not contain any material that is libellous, defamatory, or otherwise unlawful, and that it does not contain any material that invades the right of privacy, any proprietary or copyrights owned.

Patient privacy (mandatory)

X I affirm that my abstract does not contain material that reveals patient identity. If there is any chance that a patient can be identified, I confirm to have obtained written informed patient consent for use in this abstract.

Copyright and licenses (mandatory)

X I affirm that I have the right to assign license to my work.

X I further affirm that if my work contains any material that has been previously published or that is owned by a third party, I was entitled to use this material by applicable law or have obtained a transferable license from the copyright holder.

X In case that my study is under evaluation/accepted/published in a scientific journal, I understand that I am advised to consult the respective editorial office regarding copyright and license issues. I also affirm that I will acknowledge in writing (i.e. on a slide or poster, not limited to verbal acknowledgement) the interim (i.e. between abstract submission and congress presentation) acceptance/publication of the study in a scientific journal during my presentation at ECR 2024.

Co-authors agreement (mandatory)

X If my abstract is submitted on behalf of co-authors, I warrant that I was given authorisation to represent the other co-authors (co-licensors) as listed in the author line of this abstract.

Presenter registration (mandatory)

X I understand that the presenting author of each accepted abstract has to register for ECR 2024 in order to hold a presentation at the congress or have a poster presentation during congress and/or

X I understand that if this abstract is accepted as oral presentation, it will be published in the ECR 2024 Book of Abstracts (as a supplement to "Insights into Imaging", open access under the [Creative Commons Attribution License 4.0](#)).

X I understand that if this abstract is accepted as a poster, I will have to upload the digital material of my poster to EPOS™ within the given deadline. I acknowledge that the option to permanently publish my poster will be available after the congress, which will include registration with a DOI (digital object identifier) and publication under an open license as outlined in the [agreement for the use of EPOS](#).

X I understand that all abstracts which are accepted in a session during ECR 2024 will be displayed in the programme on the ECR online platform before/during the congress.

X I understand that all poster presentations at ECR 2024 will be displayed on the ECR login-protected online platform during the congress.